Introduction Candidemia is the fourth frequent reason of healthcare-related bloodstream
infections in critically ill patients. For initial management of (suspected) invasive candidiasis …

Introduction. Caspofungin is an echinocandin with proven efficacy in invasive candidiasis
(IC) and invasive aspergillosis (IA). ProCAS is a study sponsored by the Working Group of …

In critically ill patients, drug exposure may be influenced by altered drug distribution and
clearance. Earlier studies showed that the variability in caspofungin exposure was high in …

Objectives Caspofungin is used for treatment of invasive fungal infections. As the
pharmacokinetics (PK) of antimicrobial agents in critically ill patients can be highly variable …

Background: Caspofungin has shown efficacy in empirical antifungal therapy in neutropenic
patients, refractory invasive Aspergillus infections and invasive candidiasis. Here we report …

Caspofungin is a member of a new class of antifungals called Echinocandins and is the first
to have marketing authorisation in the United Kingdom. This article reviews the clinical …

Caspofungin is a common treatment for fungal infections in intensive care unit (ICU)
patients, and in these patients their pharmacokinetics are highly variable. So a rapid and …

Background Co-morbidity, medical and surgical interventions often cause alterations to drug
plasma concentrations and pharmacokinetic parameters in critically ill patients. In the …

Purpose Thirty to forty percent of patients with recurrent gastrointestinal perforation/
anastomotic leakage or acute necrotizing pancreatitis develop intra-abdominal invasive …

OBJECTIVES: The objectives of this study were to contrast risk factors, microbiology, and
outcomes in patients with invasive candidiasis treated in an intensive care unit (ICU) with …